Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.58 |
| ▸ | DRD3 | P35462 | 5/20 | 0.52 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.33 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | DRD5 | P21918 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2865406 | 1.00 | DRD2 (0.58) | DRD2SIGMAR1DRD3HTR6KIF18A | |
| SCHEMBL17411224 | 0.89 | DRD2 (0.51) | DRD2SIGMAR1DRD3HTR6KIF18A | |
| SCHEMBL15436281 | 0.85 | DRD2 (0.54) | DRD2SIGMAR1DRD3HTR6DRD1 | |
| SCHEMBL17411321 | 0.85 | DRD2 (0.58) | DRD2SIGMAR1DRD3HTR6KIF18A | |
| SCHEMBL17364178 | 0.83 | DRD2 (0.47) | DRD2SIGMAR1DRD3NR1H2NR1H3 | |
| SCHEMBL24489447 | 0.82 | DRD2 (0.56) | DRD2SIGMAR1DRD3HTR6SLC18A3 | |
| SCHEMBL24612002 | 0.79 | DRD2 (0.66) | DRD2SIGMAR1DRD3HTR6KIF18A | |
| SCHEMBL17411249 | 0.76 | DRD2 (0.51) | DRD2SIGMAR1DRD3HTR6KIF18A | |
| SCHEMBL10181371 | 0.76 | DRD2 (0.62) | DRD2SIGMAR1DRD3HTR6KIF18A | |
| SCHEMBL10180278 | 0.74 | DRD2 (0.61) | DRD2SIGMAR1DRD3HTR6NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4049998-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | Prilenia Neurotherapeutics Ltd. (IL) | 2022-08-31 | — | — | EP | disclosed |
| EP-3160470-B1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | Prilenia Neurotherapeutics Ltd (IL) | 2022-08-03 | — | — | EP | disclosed |
| US-20220023280-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | PRILENIA NEUROTHERAPEUTICS LTD. | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220023280-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | PDE3A, PDE4D, PDE9A | DRD2 14/4885SIGMAR1 142/4885DRD3 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.